Eventide Asset Management’s Beta Bionics BBNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$134M Buy
7,044,630
+790,957
+13% +$14.2M 1.87% 6
2026
Q2
$98.1M Buy
6,253,673
+308,185
+5% +$3.67M 1.31% 15
2026
Q1
$59.6M Buy
5,945,488
+950,760
+19% +$14.1M 0.99% 28
2025
Q4
$152M Buy
4,994,728
+37,476
+0.8% +$1M 2.38% 5
2025
Q3
$98.5M Buy
4,957,252
+24,901
+0.5% +$438K 1.62% 10
2025
Q2
$71.8M Buy
4,932,351
+4,332
+0.1% +$61.3K 1.26% 19
2025
Q1
$60.3M Buy
+4,928,019
New +$91.9M 1.2% 22

Other funds holding BBNX

Eventide Asset Management's BBNX Position: Q3 2026 in Review

Eventide Asset Management increased its Beta Bionics (BBNX) stake by 13% in Q3 2026, buying an estimated $14.2M and bringing the position to 7,044,630 shares worth $134M. The position accounts for 1.87% of the portfolio, ranked #6.

Eventide Asset Management first reported a position in BBNX in Q1 2025 and has held it in 7 quarters since. The position peaked at $152M in Q4 2025. 153 funds tracked by Wall St. Rank hold BBNX as of Q3 2026.

  • Eventide Asset Management held 7,044,630 shares of Beta Bionics worth $134M as of Q3 2026.
  • Eventide Asset Management bought 790,957 Beta Bionics shares in Q3 2026, an estimated $14.2M.
  • Beta Bionics made up 1.87% of Eventide Asset Management's portfolio in Q3 2026, its #6 holding.
  • Eventide Asset Management first reported a position in Beta Bionics in Q1 2025 and has held it in 7 quarters since.
  • Eventide Asset Management's Beta Bionics position peaked at $152M in Q4 2025.
  • 153 funds tracked by Wall St. Rank held Beta Bionics as of Q3 2026.

Based on Eventide Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.